

7-6-2010

Pcif1 modulates Pdx1 protein stability and pancreatic β cell function and survival in mice

Kathryn C. Claiborn

University of Pennsylvania School of Medicine

Mira M. Sachdeva

University of Pennsylvania School of Medicine

Corey E. Cannon

University of Pennsylvania School of Medicine

David N. Groff

University of Pennsylvania School of Medicine

Jeffrey D. Singer

Portland State University

See next page for additional authors

Let us know how access to this document benefits you.

Follow this and additional works at: https://pdxscholar.library.pdx.edu/bio_fac

 Part of the [Biological Phenomena, Cell Phenomena, and Immunity Commons](#), and the [Biology Commons](#)

Citation Details

Claiborn, K. C., Sachdeva, M. M., Cannon, C. E., Groff, D. N., Singer, J. D., and Stoffers, D. A. (2010). Pcif1 modulates Pdx1 protein stability and pancreatic beta cell function and survival in mice. *Journal of Clinical Investigation*, 120(10), 3713-3721

This Article is brought to you for free and open access. It has been accepted for inclusion in Biology Faculty Publications and Presentations by an authorized administrator of PDXScholar. For more information, please contact pdxscholar@pdx.edu.

Authors

Kathryn C. Claiborn, Mira M. Sachdeva, Corey E. Cannon, David N. Groff, Jeffrey D. Singer, and Doris A. Stoffers

Pcif1 modulates Pdx1 protein stability and pancreatic β cell function and survival in mice

Kathryn C. Claiborn,¹ Mira M. Sachdeva,¹ Corey E. Cannon,¹ David N. Groff,¹ Jeffrey D. Singer,² and Doris A. Stoffers¹

¹Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism and Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. ²Department of Biology, Portland State University, Portland, Oregon, USA.

The homeodomain transcription factor pancreatic duodenal homeobox 1 (Pdx1) is a major mediator of insulin transcription and a key regulator of the β cell phenotype. Heterozygous mutations in PDX1 are associated with the development of diabetes in humans. Understanding how Pdx1 expression levels are controlled is therefore of intense interest in the study and treatment of diabetes. Pdx1 C terminus–interacting factor-1 (Pcif1, also known as SPOP) is a nuclear protein that inhibits Pdx1 transactivation. Here, we show that Pcif1 targets Pdx1 for ubiquitination and proteasomal degradation. Silencing of Pcif1 increased Pdx1 protein levels in cultured mouse β cells, and Pcif1 heterozygosity normalized Pdx1 protein levels in *Pdx1*^{+/-} mouse islets, thereby increasing expression of key Pdx1 transcriptional targets. Remarkably, *Pcif1* heterozygosity improved glucose homeostasis and β cell function and normalized β cell mass in *Pdx1*^{+/-} mice by modulating β cell survival. These findings indicate that in adult mouse β cells, Pcif1 limits Pdx1 protein accumulation and thus the expression of insulin and other gene targets important in the maintenance of β cell mass and function. They also provide evidence that targeting the turnover of a pancreatic transcription factor in vivo can improve glucose homeostasis.

Introduction

The homeodomain transcription factor pancreatic duodenal homeobox 1 (Pdx1) is required for pancreas development in mice and in humans (1–4). Pdx1 is required for the specification of pancreatic progenitors after which its expression becomes restricted primarily to the insulin-producing β cell, where it plays critical roles in insulin gene transcription and insulin secretion as well as β cell survival (reviewed in ref. 5). Tight regulation of Pdx1 protein levels is necessary for Pdx1 to play its developmental and adult physiological roles. Genetic studies in which Pdx1 is conditionally inactivated in mice suggest that *Pdx1* gene dosage is critical both for development of the endocrine and exocrine pancreas and for the maintenance of adult β cells (6–8). Heterozygous loss of *Pdx1* resulting in approximately 30% reduction in protein levels is sufficient to induce impaired glucose tolerance and insulin secretion in mice, and heterozygous mutations are associated with the development of diabetes in humans (9–11). Furthermore, Pdx1 haploinsufficiency limits the β cell compensatory mechanisms that occur in response to genetic and diet-induced insulin resistance (12–14).

Much of the regulation of Pdx1 dosage occurs at the transcriptional level. Upstream regulatory elements have been described that temporally and spatially control Pdx1 expression and are required for outgrowth and differentiation of pancreatic progenitors (8, 15–20); however, posttranslational regulation of Pdx1 via phosphorylation has also been proposed to have diverse functional effects, including regulation of Pdx1 transactivation and protein stability (13, 21–25). We previously described Pdx1 C terminus–interacting factor 1 (Pcif1, also known as SPOP), a broad complex, tramtrack, bric-a-brac (BTB) domain–containing protein that interacts directly with the C terminus of Pdx1 (26, 27).

BTB-domain containing proteins have recently been identified as substrate-specific adaptors for ubiquitin ligase complexes that contain the scaffolding protein Cul3 (28, 29). We demonstrate here that the Pcif1-Cul3 complex targets Pdx1 protein for ubiquitination and proteasomal degradation. Further, we derived and characterized mice with a mutant allele of *Pcif1* (*Pcif1*^g) and found that reduction of *Pcif1* gene dosage improves glucose tolerance, normalizes β cell mass, and rescues β cell apoptosis rates in *Pdx1*^{+/-} mice while normalizing Pdx1 protein levels and the expression of Pdx1 transcriptional targets.

Results

Pcif1 targets Pdx1 for ubiquitination by a Cul3-based E3 ubiquitin ligase. BTB domain–containing proteins have been identified as substrate-specific adaptors for ubiquitin ligase complexes that include the scaffold protein Cul3 (30). The *Drosophila* ortholog of Pcif1 targets cubitus interruptus for ubiquitination, while the human ortholog SPOP has been linked to multiple targets, including the polycomb protein Bmi1 (31, 32). To determine whether a similar mechanism underlies Pcif1-mediated downregulation of Pdx1 transactivation, we utilized heterologous HEK293T cells overexpressing Pdx1 with or without coexpression of Pcif1 and Cul3. In cells overexpressing Pdx1, treatment with the proteasome inhibitor MG-132 induced a slight increase in Pdx1 protein levels, suggesting that Pdx1 protein is proteasomally degraded in this system (Figure 1A). Addition of Pcif1 and Cul3 resulted in a dramatic decrease in Pdx1 protein accumulation that was partially reversed by proteasome inhibition. Notably, the ability of Cul3 to decrease Pdx1 accumulation was attenuated by alanine substitutions for key leucine and glutamic acid residues required for interactions between Cul3 and BTB domain–containing proteins (Cul3L52AE55A) (30, 33) (Figure 1A).

To determine whether ubiquitination of Pdx1 is promoted by Pcif1 and Cul3, we employed an in vivo ubiquitination assay in HEK293T cells. Cells expressing Myc-tagged ubiquitin were sub-

Conflict of interest: Doris A. Stoffers is a co-inventor on U.S. patent nos. 6,274,310, 2001, and PCT/US08/02792, 2008. Doris A. Stoffers received an honorarium from Merck Research Labs for participation in a Global Diabetes and Obesity Expert Forum.

Citation for this article: *J Clin Invest.* 2010;120(10):3713–3721. doi:10.1172/JCI40440.




Figure 1 Pcf1 and Cul3 target Pdx1 for ubiquitination. (A) HEK293T cells were transfected with the indicated plasmids and treated with vehicle or MG-132 for 4 hours before harvest. Western blots probed for Pdx1, Flag (Cul3 and Pcif1), and Tubulin (loading control). (B–D) HEK293T cells transfected with the indicated plasmids prior to immunoprecipitation with IgG or anti-Myc–coupled agarose. Western blots probed for HA (Pdx1). Brackets indicate ubiquitinated Pdx1.


jected to immunoprecipitation with anti-Myc or isotype-matched control IgG and the products immunoblotted for Pdx1. Ubiquitination of Pdx1 was detectable as a ladder of high-molecular-weight bands that were immunoprecipitated in cells that expressed Pcif1 and Pdx1, and ubiquitination was further increased by the addition of Cul3 (Figure 1B and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI40440DS1). Cul3L52AE55A supported a minimal level of ubiquitination, consistent with the proposed role of Cul3 interaction with Pcif1 in promoting Pdx1 ubiquitination.

We previously determined that the TRAF domain of Pcif1 is required for the physical and functional interaction with Pdx1 in vitro (27). To determine whether the interaction between Pcif1 and Pdx1 was required for Pdx1 ubiquitination, we replaced full-length Pcif1 with Pcif1 lacking the TRAF domain (Pcif1Δ TRAF) in the in vivo ubiquitination system and found that the TRAF domain was required to promote Pdx1 ubiquitination (Figure 1C). Further, deletion of a conserved 28-amino-acid motif in the C terminus of Pdx1 (aa 210–238) that is required for the physical and functional interaction with Pcif1 (26, 27) abolished Pcif1-mediated ubiquitination of Pdx1 (Figure 1D). Taken together, these data strongly suggest that physical interactions among Cul3, Pcif1, and Pdx1 are required to promote Pdx1 ubiquitination.

Pcf1 regulates Pdx1 protein accumulation in Min6 β cells. The experiments described above are in agreement with those of Bunce et al, who demonstrated Pcif1-mediated ubiquitination of Pdx1 in an overexpression system (34). To determine whether endogenous Pcif1 regulates Pdx1 protein levels in β cells, we next examined the impact of Pcif1 loss of function on Pdx1 protein accumulation in

Min6 mouse insulinoma cells. shRNA-mediated silencing of Pcif1 resulted in a greater than 50% reduction in *Pcf1* transcript (Figure 2A). Compared with cells transfected with a nontargeting shRNA, endogenous Pdx1 protein levels were substantially increased in cells after Pcif1 silencing (Figure 2B). Pdx1 protein levels are critical for maintaining β cell function and mediate these effects by regulating the transcription of β cell genes such as *MafA* and the glucose transporter *Glut2* (35, 36). Downregulation of Pcif1 in Min6 cells was sufficient to induce a greater than 2-fold upregulation of *MafA* and 1.5-fold upregulation of *Glut2* transcript (Figure 2C). Insulin mRNA was not regulated under these conditions, likely due to its long half-life. Downregulation of Pcif1 in Min6 cells also extended the half-life of endogenous Pdx1, dramatically increasing protein stability over the course of a 6-hour treatment with cycloheximide (Figure 2D). Treatment of Cul3-overexpressing Min6 cells with the proteasome inhibitor LLnL induced the accumulation of high-molecular-weight ubiquitinated proteins (Figure 2E), including bands detected by Pdx1 Western blot that may represent polyubiquitinated Pdx1. Accumulation of this species was abolished upon Pcif1 knockdown (Figure 2E, left panel). Probing Pdx1 immunoprecipitates from LLnL-treated Min6 cells with an anti-ubiquitin antibody revealed the presence of a high-molecular-weight (~98 kDa) band that was substantially diminished upon Pcif1 knockdown (Supplemental Figure 2). These data suggest that Pcif1-mediated regulation of endogenous Pdx1 protein levels directly impacts Pdx1 protein ubiquitination, accumulation, and stability and the expression of key Pdx1 target genes.

Derivation of a Pcif1 gene trap allele. To investigate the role of Pcif1 in vivo, we generated mice from an ES cell clone containing

**Figure 2**

Increased Pdx1 accumulation and stability in *Pcf1*-deficient Min6 β cells and embryonic pancreas. (A–C) Min6 cells nucleofected with control nontargeting shRNA (shNT) or sh*Pcf1*. (A) *Pcf1* transcript measured by QPCR and normalized to *Hprt*. $n = 3$, $^{**}P < 0.01$. (B) Western blot probed for Pdx1 and tubulin (loading control). (C) Transcript levels of Pdx1 transcriptional targets *MafA* and *Glut2*. $n = 3$, $^{**}P < 0.01$. (D) Min6 cells expressing shNT or sh*Pcf1*, treated with the translation inhibitor cyclohexamide (CHX) and harvested at the time points indicated. Western blots are probed for Pdx1 and Ran (loading control). (E) Min6 cells overexpressing *Cul3* and nontargeting shRNA or sh*Pcf1* were treated with vehicle or 20 μ M LLnL for 8 hours. Western blots are probed for Pdx1 (left) and ubiquitin (right). (F) Fluorescence staining of E16.5 embryos with dilute Pdx1 antibody. Original magnification $\times 10$. (G) β Cell area of E18.5 embryos. $n = 6$, $^{**}P < 0.01$ compared with *Pcf1*^{+/+}.

a gene trap insertion in the first intron of the *Pcf1* locus. Mice heterozygous for the gene trap allele (*Pcf1*^{+/gt}) were viable and fertile. In heterozygous crosses, *Pcf1*^{gt/gt} embryos harvested at E18.5 were found at Mendelian ratios ($n = 372$); however, no viable *Pcf1*^{gt/gt} mice were found after postnatal day 1, indicating that homozygous loss of *Pcf1* results in postnatal lethality. At E18.5, *Pcf1*^{gt/gt} embryos displayed normal body and pancreas weight and normal blood sugar (Supplemental Figure 3).

The gene trap insertion cassette contains a strong splice acceptor sequence followed by the β Geo reporter and ends with a polyadenylation signal. The transcript generated by the gene trap should prevent splicing between exons 1 and 2, thereby blocking the generation of the normal *Pcf1* transcript. Using primers that span exons 1 and 2, *Pcf1* transcript levels were reduced by greater than 50% in E18.5 pancreas and lung from heterozygous animals and undetectable in *Pcf1*^{gt/gt} tissues (Supplemental Figure 4, A and B). Similar reductions in *Pcf1* protein were observed in Western blots of embryonic kidney lysates (Supplemental Figure 4C). No *Pcf1* transcript was detected in *Pcf1*^{gt/gt} tissues using primers spanning exons 7 and 8 (data not shown), indicating that the gene trap efficiently prevents the generation of a protein-coding *Pcf1* transcript.

Transcript analysis indicated that *Pcf1* is expressed during embryonic pancreas development (data not shown). To deter-

mine whether *Pcf1* modulates Pdx1 protein accumulation during development, we assessed staining intensity in sections from E16.5 and E18.5 embryos using an anti-Pdx1 antibody at a dilution that enabled semiquantitative evaluation of Pdx1 protein levels. Pdx1 staining intensity was markedly increased in all pancreatic lineages in *Pcf1*^{gt/gt} mice at these stages (Figure 2F and data not shown). Further, mice homozygous for the *Pcf1* gene trap allele demonstrated an approximately 3-fold increase in relative β cell area at E18.5 (Figure 2G), consistent with previously established roles of Pdx1 protein level in regulating endocrine progenitor specification and lineage allocation during pancreatic development (7, 8, 37, 38). There was no significant change in β cell area in the *Pcf1*^{+/gt} mice at this stage of development (Figure 2E).

Increased Pdx1 protein levels in *Pcf1*^{+/gt}*Pdx1*^{+/-} mouse islets. To determine whether *Pcf1* regulates Pdx1 protein levels in adult β cells in vivo, we intercrossed *Pcf1*^{+/gt} and *Pdx1*^{+/-} mice and analyzed islets isolated from wild-type, *Pcf1*^{+/gt}, *Pdx1*^{+/-}, and *Pcf1*^{+/gt}*Pdx1*^{+/-} littermates (Figure 3, A and B). In agreement with a study by Brissova et al. (10), Pdx1 protein levels were reduced in *Pdx1*^{+/-} islets compared with those of wild-type littermates, whereas Pdx1 protein levels were normalized in *Pcf1*^{+/gt}*Pdx1*^{+/-} islets. Pdx1 transcript levels were not affected by *Pcf1* genotype, consistent with the hypothesis that *Pcf1*-mediated regulation of Pdx1 occurs posttranscription-




Figure 3

Pcif1 regulates Pdx1 protein accumulation and Pdx1 target gene expression in primary mouse islets. (A) Western blot of islets isolated from individual mice, probed for Pdx1. (B) Quantification of Western blots of islet protein extracts, normalized to loading control. $n = 4$, $*P < 0.05$. (C) Pdx1 and *Pcif1* transcript levels in isolated mouse islets. $n = 5-8$, $*P < 0.05$, $**P < 0.01$ compared with wild-type. (D) Insulin transcript level in mouse islets. $n = 5-8$, $**P < 0.01$.

ally (Figure 3C). Further, the normalization of Pdx1 protein levels in *Pcif1^{+/-}Pdx1^{+/-}* islets was associated with normalization of pre-mRNA level for insulin1, a key Pdx1 transcriptional target (Figure 3D). These data demonstrate that *Pcif1* regulates the accumulation of Pdx1 protein in the adult β cell and may thus modulate the actions of Pdx1 as a critical regulator of glucose homeostasis.

Pcif1 heterozygosity normalizes β cell mass and improves β cell survival in *Pdx1^{+/-}* mice. *Pdx1^{+/-}* mice were previously reported to exhibit an age-related decline in β cell mass due to impaired β cell survival (39). Examination of islet architecture in *Pdx1^{+/-}* pancreata revealed the previously described “mixed islet” phenotype, with glucagon-positive α cells scattered throughout the core of the islet; this defect was not normalized in *Pcif1^{+/-}Pdx1^{+/-}* mice (Figure 4A). We quantified β cell mass by determining the relative area occupied by insulin staining of pancreatic sections and observed a marked decrease in the cross-sectional area stained by insulin in *Pdx1^{+/-}* pancreas compared with all other genotypes. Upon quantification, *Pcif1^{+/-}* mice were found to have β cell mass similar to that of wild-type littermates, whereas *Pdx1^{+/-}* mice displayed a greater than 50% decrease in β cell mass compared with wild-type and *Pcif1^{+/-}* mice (Figure 4B). Notably, *Pcif1* heterozygosity normalized the reduced β cell mass of *Pdx1^{+/-}* mice. This was accompanied by a reduction in the rate of apoptotic β cells in *Pcif1^{+/-}Pdx1^{+/-}* mice as compared with *Pdx1^{+/-}* mice (Figure 5A).

To determine whether the rescue of β cell area in *Pcif1^{+/-}Pdx1^{+/-}* was associated with changes in islet size, we determined the distribution of islet size in all genotypes. Although average islet size was not different among genotypes (data not shown), *Pdx1^{+/-}* mice had a dramatic increase in the number of small (101–250 μm^2) islets and a corresponding decrease in the percentage of medium-sized (1,001–2,500 μm^2) and large (>25,000 μm^2) islets (Figure 4C). Notably, each of these differences in islet size distribution was normalized in *Pcif1^{+/-}Pdx1^{+/-}* mice (Figure 4C).

In *Pcif1^{+/-}* mice, the finding of increased β cell apoptosis in the setting of normal β cell mass (Figure 4B and Figure 5A) suggested that β cell replication may also be influenced by *Pcif1* gene dosage. Indeed, *Pcif1^{+/-}* mice displayed an increase in the rate

of β cell replication compared with wild-type littermates; however, the rates of BrdU incorporation were not different among *Pcif1^{+/-}*, *Pdx1^{+/-}*, and *Pcif1^{+/-}Pdx1^{+/-}* mice (Figure 5B). The finding of increased β cell replication in *Pcif1^{+/-}* mice was confirmed by quantification of Ki67 and phospho-histone H3-positive β cells (Supplemental Figure 5, A and B). We also observed a modest but significant decrease in average β cell size in *Pdx1^{+/-}* mice that was not altered in the context of *Pcif1* heterozygosity (Figure 5C). Taken together, these data indicate that the normalization of β cell mass observed in *Pcif1^{+/-}Pdx1^{+/-}* mice is due primarily to a reduction in the rate of apoptosis.

To determine whether the effect of *Pcif1* heterozygosity on β cell turnover was age dependent, we assessed the β cell replication rate of each genotype in 5-week-old mice. Notably, we observed no differences in BrdU incorporation among genotypes at this age (Supplemental Figure 6). In these adolescent animals, pancreas size and β cell apoptosis rates as assessed by TUNEL staining were extremely low, precluding rigorous evaluation; preliminary analysis did not reveal differences based on genotype (data not shown). Taken together, these data suggest that the effect of *Pcif1* heterozygosity on β cell replication rates is age dependent and that *Pcif1* deficiency improves the age-related decline in β cell mass previously observed in *Pdx1^{+/-}* mice (39).

Pcif1 deficiency reduces ER stress-associated apoptosis in *Pdx1*-deficient β cells. Pdx1 deficiency was recently shown to result in increased susceptibility to ER stress-induced apoptosis in β cells (14). To determine whether improved ER homeostasis contributed to the improvement in β cell survival in *Pcif1^{+/-}Pdx1^{+/-}* mice, we measured mRNA levels of the ER chaperone protein Bip in islets isolated from each genotype. As recently described (14), we observed an increase in *Bip* mRNA levels in *Pdx1^{+/-}* islets compared with those of wild-type littermates (Figure 6A). *Bip* mRNA levels were normalized in *Pcif1^{+/-}Pdx1^{+/-}* compared with *Pdx1^{+/-}* islets, suggesting that improved ER homeostasis may underlie the improved β cell survival in transheterozygous animals. In support of this finding, knockdown of endogenous Pdx1 protein in Min6 cells resulted in increased cleavage of the ER-resident caspase-12, while simultane-




Figure 4
Pcf1 heterozygosity normalizes β cell mass in *Pdx1*^{+/-} mice. (A) Representative images of insulin- and glucagon-stained adult pancreas sections. Original magnification $\times 20$. (B) Quantification of β cell mass. $n = 7-10$ mice per group; * $P < 0.05$ compared with wild-type. (C) Islet size distribution. $n = 7-9$ mice per group; * $P < 0.05$, ** $P < 0.01$ compared with wild-type.

ous knockdown of *Pcf1* restored *Pdx1* protein to control levels and prevented caspase-12 cleavage (Figure 6B).

Pcf1 heterozygosity improves glucose homeostasis in *Pdx1*^{+/-} mice. To determine whether the observed normalization of β cell mass in *Pcf1*^{+/gt}*Pdx1*^{+/-} mice is associated with improved β cell function, we assessed glucose tolerance and insulin secretion. Male and female *Pcf1*^{+/gt} mice displayed normal glucose tolerance upon intraperitoneal glucose tolerance testing, and *Pdx1*^{+/-} mice were glucose intolerant as previously described (Figures 7, A and B). The glucose intolerance phenotype of *Pdx1*^{+/-} mice was significantly improved in both male and female *Pcf1*^{+/gt}*Pdx1*^{+/-} transheterozygous mice. All genotypes displayed similar insulin sensitivity, determined by insulin tolerance testing (Figures 7, C and D), suggesting

that the observed alterations in glucose tolerance were due to differences in insulin secretion; therefore, acute glucose-stimulated insulin secretion was assessed in vivo. As expected, *Pdx1*^{+/-} mice displayed a blunted insulin secretory response to glucose. Notably, the defect in *Pdx1*^{+/-} mice was attenuated, though not fully rescued, in *Pcf1*^{+/gt}*Pdx1*^{+/-} mice (insulin AUC: *Pdx1*^{+/-} vs. *Pcf1*^{+/gt}*Pdx1*^{+/-}, 373 ± 44 vs. 595 ± 58 pM min; $P < 0.05$) (Figure 7E).

To determine whether *Pcf1* heterozygosity directly influences islet function, we further analyzed insulin secretion in isolated islets. Wild-type and *Pcf1*^{+/gt} islets displayed a significant glucose stimulation of insulin secretion in static incubations (Figure 7F). Although *Pdx1*^{+/-} islets were previously reported to display normal insulin secretion ex vivo, we observed a blunted response




Figure 5
 Normalized β cell mass is mediated by improved survival in *Pcf1*^{+/gt}*Pdx1*^{+/-} mice. (A) Apoptosis measured by quantifying insulin- and TUNEL-copositive cells. (B) β Cell replication measured by quantifying insulin and BrdU double positive cells. (C) β Cell size calculated by dividing insulin-positive islet area by the number of DAPI-stained nuclei counted within that area. All morphometric analyses performed on pancreas sections from 16-week-old male mice. $n = 5-8$ per group; * $P < 0.05$, ** $P < 0.01$ compared with wild-type.




Figure 6
Pcif1 deficiency improves ER homeostasis in *Pdx1*-deficient β cells. **(A)** *Bip* mRNA levels as a measure of ER stress in isolated islets, normalized to *Hprt*. $n = 7$ per group; * $P < 0.05$ compared with wild-type. **(B)** Western blot for *Pdx1* and the ER-resident caspase-12 after *Pcif1* or *Pdx1* knockdown in Min6 cells.

after static incubation (1.76 ± 0.26 -fold over basal secretion; $P = \text{NS}$). Glucose-stimulated insulin secretion was restored in *Pcif1*^{+/g}*Pdx1*^{-/-} islets (2.76 ± 0.4 -fold over basal secretion, $P = 0.07$) (Figure 7F). These data suggest that *Pcif1* haploinsufficiency improves glucose responsiveness in *Pdx1*^{-/-} β cells.

Pcif1 regulation of *Pdx1* protein levels is regulated by glucose. The increase in *Pdx1* protein level that followed shRNA-mediated *Pcif1* silencing in Min6 cells (Figure 2B and Figure 8A) was observed in cells cultured in low-glucose-containing medium (5.5 mM). Although Min6 cells chronically maintained in high glucose exhibit levels of *Pcif1* similar to those maintained in low glucose (Supplemental Figure 7), *Pcif1* silencing in Min6 cells cultured in high-glucose medium (25 mM) did not significantly alter endogenous *Pdx1* protein levels (Figure 8A), suggesting that *Pcif1* modulation of *Pdx1* protein accumulation is regulated by glucose. In addition, the level of *Pdx1* protein was increased in high-glucose- compared with low-glucose-cultured cells, in agreement with recent findings by Humphrey et al. demonstrating that *Pdx1* protein is stabilized in Min6 cells and primary islets cultured under high-glucose conditions (25). Similarly, we found that in the HEK293T overexpression system, the previously observed effect of *Pcif1* and *Cul3* on *Pdx1* protein accumulation (Figure 1A) was amplified in cells cultured in 5.5 mM glucose as compared with standard (25 mM glucose) conditions (Figure 8B). In agreement with these findings, overexpressed *Pdx1* more readily coimmunoprecipitated with Flag-tagged *Pcif1* in cells cultured in low glucose (Figure 8C), suggesting that decreased interaction between *Pcif1* and *Pdx1* in high-glucose conditions may underlie the increase in *Pdx1* protein accumulation in those cells.

In primary mouse islets, overnight culture in high glucose (30 mM) resulted in an approximately 50% decrease in *Pcif1* mRNA, which corresponded to a posttranscriptional increase in *Pdx1* protein (Supplemental Figure 8, A and B). This increase in *Pdx1*

protein was associated with a greater than 10-fold increase in insulin mRNA level (Supplemental Figure 8C), suggesting that acute glucose regulation of *Pcif1* transcription could contribute to the posttranscriptional increase in *Pdx1* protein levels and increased expression of *Pdx1* transcriptional targets. Taken together, these data suggest that glucose modulation of *Pdx1* protein accumulation involves multiple mechanisms including regulation of levels of and interaction with *Pcif1*.

Discussion

Here, we demonstrate that *Pcif1*, a BTB domain protein partner of *Pdx1*, directly contributes to the accumulation of *Pdx1* protein in the adult β cell and thus to the actions of *Pdx1* as a critical regulator of glucose homeostasis. Our results demonstrate that *Pcif1* and *Cul3* cooperatively target *Pdx1* for ubiquitination and proteasomal degradation and that *Pcif1* deficiency increases *Pdx1* protein levels and stability in Min6 cells and in the developing pancreas and adult islets in vivo. Normalization of *Pdx1* protein levels in *Pcif1*^{+/g}*Pdx1*^{-/-} transheterozygous mice was associated with improved β cell function and mass, leading to improved glucose tolerance and insulin secretion in *Pdx1*^{-/-} mice. The improvement in β cell mass was due to an attenuation of the survival defect caused by *Pdx1* deficiency and associated with an improvement in ER homeostasis. These results provide genetic evidence of posttranscriptional regulation of *Pdx1* as a mediator of glucose homeostasis and of β cell survival in vivo.

Pcif1 heterozygosity completely rescued β cell mass and islet insulin transcript levels in *Pdx1*^{-/-} mice but mediated only a partial rescue of insulin secretion and thus glucose tolerance. Further, the defect in islet architecture observed in *Pdx1*^{-/-} mice was not normalized. These discrepancies may reflect different thresholds of *Pdx1* required for optimal activation of *Pdx1* transcriptional targets involved in islet development, insulin secretion, and β cell growth and survival. Our analysis of *Pcif1*^{g/g} embryos demonstrated that although *Pcif1* is not required for pancreatic organogenesis, it does influence the formation of developing β cells; however, the spatial and temporal sequence of *Pcif1* expression in the pancreas has not yet been fully elucidated, and thus the relative importance of *Pcif1* in regulation of the multiple roles of *Pdx1* in the developing pancreas merits further investigation.

Although our findings suggest that the improved glucose homeostasis in *Pcif1*^{+/g}*Pdx1*^{-/-} mice is due to rescue of islet *Pdx1* protein levels and thus improved β cell mass and function, the data also suggest a complex role for *Pcif1* in the maintenance of β cell mass. *Pcif1*^{+/g} mice displayed normal β cell mass, but also balanced increases in both β cell replication and apoptosis rates. Furthermore, *Pcif1* heterozygosity induced an increased rate of β cell replication that was not affected in the setting of *Pdx1* heterozygosity, indicating roles of *Pcif1* in β cell replication, and perhaps apoptosis, that may be independent of its regulation of *Pdx1* protein accumulation. In addition, *Pcif1* heterozygosity had no effect on β cell replication in younger (5-week-old) mice, pointing to a role in age-dependent replication rates. The human ortholog of *Pcif1*, SPOP, has been implicated in the ubiquitination of multiple targets, including the polycomb group protein *Bmi1* (32), recently implicated in pancreatic β cell proliferation via its control of the *Ink4a/Arf* locus (40, 41). SPOP has also been described to ubiquitinate the proapoptotic protein *Daxx* (42). Thus, the contribution of *Pcif1* to the β cell-replicative and apoptotic rates may be due to regulation of *Bmi1*, *Daxx*, or other, as-yet-undiscovered ubiquitination targets.




Figure 7 *Pcif1* heterozygosity improves glucose homeostasis and β cell function in *Pdx1^{+/-}* mice. (A) Intraperitoneal glucose tolerance of male mice (7–8 weeks old). $n = 6–9$ per group; $P < 0.05$, *Pdx1^{+/-}* versus *Pcif1^{+/-}Pdx1^{+/-}*, by ANOVA. (B) Intraperitoneal glucose tolerance of female mice (10–12 weeks old). $n = 6–11$ per group; $P < 0.001$, *Pdx1^{+/-}* versus *Pcif1^{+/-}Pdx1^{+/-}* by ANOVA. (C) Insulin tolerance of male mice (8–9 weeks old). $P = NS$ for all groups. (D) Insulin tolerance of female mice (11–13 weeks old). $P = NS$ for all groups. (E) Acute glucose-stimulated insulin secretion calculated as AUC for 15 minutes after glucose bolus (12-week-old male mice). $n = 7–12$ per group, $*P < 0.05$, $**P < 0.01$. (F) Glucose-stimulated insulin secretion during static incubations of isolated islets from 6- to 8-week-old male mice. Insulin secretion values were normalized to islet insulin content and expressed as fold stimulation. $n = 3–6$ mice per group, $*P < 0.05$.

Our findings indicate that in adult β cells, *Pcif1* limits *Pdx1* protein accumulation and thus the expression of insulin and other gene targets critical to the maintenance of β cell mass and function. The identification of this new *Pdx1* regulatory mechanism and validation of its role in vivo suggest that the therapeutic targeting of *Pcif1*-Cul3-mediated turnover of *Pdx1* could raise *Pdx1* protein levels to improve β cell function and viability in the treatment of diabetes.


Methods

Animals and physiological experiments. Mouse ES cells containing a gene trap insertion in the first intron of *Pcif1* were purchased from BayGenomics

(clone Bgb118). Mice were derived by injection of ES cells into blastocysts by the University of Pennsylvania Transgenic and Chimeric Mouse Facility. Animals were housed in the animal care facility at the University of Pennsylvania and maintained on a 12-hour light/12-hour dark cycle with ad libitum access to food and water. All experiments described were performed on mice of a mixed 129/Sv \times C57BL/6 background. For embryonic studies, the date of vaginal plug was considered E0.5. For glucose tolerance tests, animals were fasted for 16 hours before delivery of a 2-g/kg glucose bolus. Blood glucose was measured by handheld glucometers (Freestyle/One Touch). Serum was collected during the glucose tolerance test and insulin assessed by ELISA (Chemicon). For insulin tolerance tests, animals

Figure 8

Posttranscriptional regulation of *Pdx1* protein level by glucose. (A) Western blot of lysates from Min6 cells maintained in 5.5 or 25 mM glucose, expressing nontargeting shRNA or shPCIF1. Blots are probed for *Pdx1* and Ran (loading control). (B) Western blot of lysates from HEK293T cells maintained in 5.5 or 25 mM glucose, expressing *Pdx1* in the presence or absence of overexpressed *Pcif1* and Cul3. Blots are probed for *Pdx1* and Ran. (C) HEK293T cells maintained in 5.5 or 25 mM glucose, transfected with plasmids expressing *Pdx1* and Flag-*Pcif1*, and subjected to immunoprecipitation with IgG or *Pdx1* antisera. Western blots are probed for *Pdx1* or Flag (*Pcif1*). Arrow indicates migration of Flag-*Pcif1*; asterisk indicates heavy chain IgG signal.





were fasted for 6 hours prior to an i.p. injection of 0.75 U/kg insulin. All animal procedures were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.

Pancreas morphometry. BrdU was administered in the drinking water (1 g/l) for 1 week prior to sacrifice. Five- and 16-week-old male mice were anesthetized and the pancreas dissected rapidly, weighed, and fixed overnight in 4% paraformaldehyde. Paraffin sections were stained for insulin (Linco), BrdU (US Biologicals), and TUNEL (Chemicon Apoptag Peroxidase In Situ Kit). For β cell mass measurements, whole slide images of insulin-stained sections were captured on an Aperio slide scanner and the stained area quantified using Image-Pro software (Media Cybernetics). The percentage of insulin-stained area was then multiplied by pancreas weight to obtain an estimate of β cell mass. For replication measurements, an average of 1,119 and 1,463 β cells were counted per animal in the 5- and 16-week-old cohorts, respectively. For apoptosis measurements, an average of 2,398 β cells were counted per animal. For Ki67 and pHH3 confirmation of replication measurements, an average of 2,381 and 2,715 cells were counted per animal, respectively.

Islet isolation. Islets were isolated from 8- to 12-week-old mice by collagenase digestion followed by 3–4 rounds of hand picking. For RNA and protein analysis, samples were matched for islet purity by measuring amylase and insulin transcript levels. For static incubations, 5 islets were analyzed in triplicate from each animal. Islets were incubated in glucose-free KRBB buffer for 1 hour before the addition of 1.67 mM glucose. Samples were taken after 1 hour of incubation, and glucose was added to a final concentration of 16.7 mM. After 1 hour of stimulation, secretion samples were collected and islets were harvested in islet lysis buffer and analyzed for insulin content. Insulin secretion and content were measured by ELISA (Chemicon).

Cell culture and transfections. Min6 β cells were cultured in DMEM with 5.5 mM or 25 mM glucose (Invitrogen) supplemented with 10% FBS and used between passages 25 and 35. For knockdown experiments, cells were nucleofected by AMAXA with predesigned shRNA plasmids directed against Pcf1 or a nontargeting control (Sigma-Aldrich shPcf1 TRCN0000124643: CCGGGTAAACCCGAAAGGGCTAGATCTCGA-GATCTAGCCCTTTCGGGTTTACTTTTTG). After 72 hours, cells were harvested for protein and RNA. HEK293T cells were cultured in high-glucose DMEM under standard conditions. For expression assays, cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions, and protein was harvested after 48 hours. For proteasome inhibition, 10 μ M MG-132 (Calbiochem) or vehicle (DMSO) was added to the medium 4 hours before harvest. For proteasome inhibition in Min6 cells, 20 μ M LLnL (Sigma-Aldrich) or vehicle (DMSO) was added to medium 8 hours before harvest.

In vivo ubiquitination assay and coimmunoprecipitation. HEK293T cells were transfected as described above. After 48 hours, cells were harvested in RIPA

buffer and subjected to immunoprecipitation with mouse α -Myc-coupled agarose beads or mouse IgG-coupled control beads (Santa Cruz Biotechnology Inc.). To assess Pcf1-Pdx1 interaction, HEK293T cells were transfected as described above and subjected to immunoprecipitation with goat α -Pdx1 antibody or goat IgG (Santa Cruz Biotechnology Inc.) 48 hours later.

Western blots and antisera. Proteins were separated by SDS-PAGE and immunoblotted with the following antibodies: rabbit anti-Pcf1 (26), mouse anti-tubulin (Sigma-Aldrich), rabbit anti-Pdx1 (43), mouse anti-Flag epitope (Sigma-Aldrich), rabbit anti-HA epitope (Santa Cruz Biotechnology Inc.), rabbit anti-ubiquitin (Dako), rat anti-caspase-12 (Sigma-Aldrich), and mouse anti-Ran (BD Biosciences).

RNA isolation and transcript analysis. Embryonic tissues were harvested and stored in RNeasy lysis buffer (Qiagen), then homogenized in TRIzol (Invitrogen) and processed according to the manufacturer's instructions. Islet RNA was extracted using the RNeasy Mini Kit (Qiagen). All samples were reverse transcribed using SuperScript (Invitrogen) and oligo(dT) for priming. Transcript was analyzed by quantitative PCR and normalized to the *Hprt* transcript as an internal control. For isolated islets, samples were purity matched by comparing insulin and amylase transcripts.

Statistics. Data are presented as mean \pm SEM. Differences between groups were compared by 2-tailed Student's *t* tests and considered significant when *P* values were less than 0.05. Group measurements of glucose and insulin tolerance were compared by factorial ANOVA.

Acknowledgments

We thank K.H. Kaestner for critical reading of the manuscript and for assistance with ES cell culture, C.V. Wright (Vanderbilt University) for providing us with the *Pdx1*^{+/-} mice, and Jean Richa of the University of Pennsylvania Chimeric and Transgenic Mouse Facility for blastocyst injection. We received technical assistance in image capture and analysis from G. Swain of the Morphology Core (P30-DK050306) and D. Martinez of the Pathology Core at the Children's Hospital of Philadelphia. This work was supported by NIH NIDDK grants R01 DK068157 and P01 DK049210 (to D.A. Stoffers) and NIH grant T32-GM07229 (to K.C. Claiborn).

Received for publication July 8, 2009, and accepted in revised form July 16, 2010.

Address correspondence to: Doris A. Stoffers, Institute for Diabetes, Obesity and Metabolism, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Clinical Research Building #700, University of Pennsylvania School of Medicine, 415 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. Phone: 215.573.5413; Fax: 215.898.5408; E-mail: stoffers@mail.med.upenn.edu.

- Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. *Development*. 1996; 122(5):1409–1416.
- Offield MF, et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development*. 1996;122(3):983–995.
- Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. *Nat Genet*. 1997;15(1):106–110.
- Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature*. 1994;371(6498):606–609.
- Babu DA, Deering TG, Mirmira RG. A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis. *Mol Genet Metab*. 2007;92(1–2):43–55.
- Hale MA, et al. The homeodomain protein PDX1 is required at mid-pancreatic development for the formation of the exocrine pancreas. *Dev Biol*. 2005; 286(1):225–237.
- Holland AM, Gopez LJ, Naselli G, Macdonald RJ, Harrison LC. Conditional expression demonstrates the role of the homeodomain transcription factor Pdx1 in maintenance and regeneration of beta-cells in the adult pancreas. *Diabetes*. 2005;54(9):2586–2595.
- Fujitani Y, et al. Targeted deletion of a cis-regulatory region reveals differential gene dosage requirements for Pdx1 in foregut organ differentiation and pancreas formation. *Genes Dev*. 2006;20(2):253–266.
- Hani EH, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. *J Clin Invest*. 1999;104(9):R41–R48.
- Brissova M, et al. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. *J Biol Chem*. 2002;277(13):11225–11232.
- Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. *Nat Genet*. 1997;17(2):138–139.
- Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, Kahn CR. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. *J Clin Invest*. 2004;114(6):828–836.
- Brissova M, et al. Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis. *Am J Physiol Endocrinol Metab*. 2005;288(4):E707–E714.
- Sachdeva MM, et al. Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress. *Proc Natl Acad Sci U S A*. 2009;106(45):19090–19095.
- Sharma S, Leonard J, Lee S, Chapman HD, Leiter



- EH, Montminy MR. Pancreatic islet expression of the homeobox factor STF-1 relies on an E-box motif that binds USF. *J Biol Chem*. 1996;271(4):2294-2299.
16. Sharma S, Jhala US, Johnson T, Ferreri K, Leonard J, Montminy M. Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. *Mol Cell Biol*. 1997;17(5):2598-2604.
17. Gerrish K, Van Velkinburgh JC, Stein R. Conserved transcriptional regulatory domains of the pdx-1 gene. *Mol Endocrinol*. 2004;18(3):533-548.
18. Boyer DF, Fujitani Y, Gannon M, Powers AC, Stein RW, Wright CV. Complementation rescue of Pdx1 null phenotype demonstrates distinct roles of proximal and distal cis-regulatory sequences in pancreatic and duodenal expression. *Dev Biol*. 2006;298(2):616-631.
19. Gao N, LeLay J, Vatamaniuk MZ, Rieck S, Friedman JR, Kaestner KH. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. *Genes Dev*. 2008;22(24):3435-3448.
20. Gerrish K, et al. Pancreatic beta cell-specific transcription of the pdx-1 gene. The role of conserved upstream control regions and their hepatic nuclear factor 3beta sites. *J Biol Chem*. 2000;275(5):3485-3492.
21. Petersen HV, et al. Glucose stimulates the activation domain potential of the PDX-1 homeodomain transcription factor. *FEBS Lett*. 1998;431(3):362-366.
22. Lebrun P, Montminy MR, Van Obberghen E. Regulation of the pancreatic duodenal homeobox-1 protein by DNA-dependent protein kinase. *J Biol Chem*. 2005;280(46):38203-38210.
23. Boucher MJ, Selander L, Carlsson L, Edlund H. Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. *J Biol Chem*. 2006;281(10):6395-6403.
24. Kishi A, Nakamura T, Nishio Y, Maegawa H, Kashiwagi A. Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. *Am J Physiol Endocrinol Metab*. 2003;284(4):E830-E840.
25. Humphrey RK, Yu SM, Flores LE, Jhala US. Glucose regulates steady-state levels of PDX1 via the reciprocal actions of GSK3 and AKT kinases. *J Biol Chem*. 2010;285(5):3406-3416.
26. Liu A, Desai BM, Stoffers DA. Identification of PCIF1, a POZ domain protein that inhibits PDX-1 (MODY4) transcriptional activity. *Mol Cell Biol*. 2004;24(10):4372-4383.
27. Liu A, Oliver-Krasinski J, Stoffers DA. Two conserved domains in PCIF1 mediate interaction with pancreatic transcription factor PDX-1. *FEBS Lett*. 2006;580(28-29):6701-6706.
28. Pintard L, et al. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. *Nature*. 2003;425(6955):311-316.
29. Krek W. BTB proteins as henchmen of Cul3-based ubiquitin ligases. *Nat Cell Biol*. 2003;5(11):950-951.
30. Xu L, et al. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. *Nature*. 2003;425(6955):316-321.
31. Zhang Q, Zhang L, Wang B, Ou CY, Chien CT, Jiang J. A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. *Dev Cell*. 2006;10(6):719-729.
32. Hernandez-Munoz I, et al. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CUL3/SPOP ubiquitin E3 ligase. *Proc Natl Acad Sci U S A*. 2005;102(21):7635-7640.
33. Zheng N, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. *Nature*. 2002;416(6882):703-709.
34. Bunce MW, Boronenkov IV, Anderson RA. Coordinated activation of the nuclear ubiquitin ligase Cul3-SPOP by the generation of phosphatidylinositol 5-phosphate. *J Biol Chem*. 2008;283(13):8678-8686.
35. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. β -Cell-specific inactivation of the mouse Ipfl/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. *Genes Dev*. 1998;12(12):1763-1768.
36. Raum JC, et al. FoxA2, Nkx2.2, and PDX-1 regulate islet beta-cell-specific mafA expression through conserved sequences located between base pairs -8118 and -7750 upstream from the transcription start site. *Mol Cell Biol*. 2006;26(15):5735-5743.
37. Holland AM, Hale MA, Kagami H, Hammer RE, MacDonald RJ. Experimental control of pancreatic development and maintenance. *Proc Natl Acad Sci U S A*. 2002;99(19):12236-12241.
38. Oliver-Krasinski JM, et al. The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. *J Clin Invest*. 2009;119(7):1888-1898.
39. Johnson JD, et al. Increased islet apoptosis in Pdx1^{+/-} mice. *J Clin Invest*. 2003;111(8):1147-1160.
40. Chen H, et al. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. *Genes Dev*. 2009;23(8):975-985.
41. Dhawan S, Tschien SI, Bhushan A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. *Genes Dev*. 2009;23(8):906-911.
42. Kwon JE, et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. *J Biol Chem*. 2006;281(18):12664-12672.
43. Stoffers DA, Stanojevic V, Habener JF. Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein. *J Clin Invest*. 1998;102(1):232-241.

Copyright of Journal of Clinical Investigation is the property of American Society for Clinical Investigation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.